9don MSN
Rallybio shares successful early-stage results for rare disease drug; new trial set for late 2026
Rallybio Corporation RLYB on Tuesday shared results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) ...
Chennai: People whose immune systems mount an unusually aggressive early response to tuberculosis may be less likely to respond well to standard drug .
A team led by the University of Sydney has identified red blood cell rupture at dying endothelial sites as a primary driver of microvascular obstruction in COVID-19, bypassing the expected role of ...
Your immune system is like an incredibly sophisticated security team, constantly patrolling your body for threats and neutralizing them before they can cause harm. When it’s working properly, this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results